Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty

Arteriosclerosis, Thrombosis, and Vascular Biology
Cory Messerschmidt, Richard J Friedman

Abstract

Anticoagulant medications help to reduce the risk of thromboembolic events after total hip arthroplasty and total knee arthroplasty. Traditionally, this has been accomplished with medications, such as low-molecular-weight heparin and warfarin. However, these traditional anticoagulants possess a variety of shortcomings that leave much room for improvement. A new class of oral anticoagulants is now available, and present a more convenient option for safe and efficacious thromboprophylaxis in post arthroplasty patients, particularly in the outpatient setting. This review focuses on the direct thrombin inhibitor, dabigatran, and the selective factor Xa inhibitors, rivaroxaban and apixaban, and the clinical data to date about their use in total hip arthroplasty and total knee arthroplasty patients.

References

Jul 1, 1996·Annals of Internal Medicine·P PrandoniM H Prins
Feb 7, 2001·Chest·W H GeertsH B Wheeler
Jan 17, 2002·The New England Journal of Medicine·K A BauerUNKNOWN Steering Committee of the Pentasaccharide in Major Knee Surgery Study
Jun 7, 2002·Lancet·Michael Rud LassenUNKNOWN European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee
Jan 27, 2004·The Annals of Pharmacotherapy·Gerry OsterJohn Edelsberg
May 28, 2004·The New England Journal of Medicine·Vittorio PengoUNKNOWN Thromboembolic Pulmonary Hypertension Study Group
Jun 29, 2004·Journal of Thrombosis and Haemostasis : JTH·P MismettiM Cucherat
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Dagmar KubitzaGeorg Wensing
Nov 17, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechWilly Roth
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators
Oct 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nirmala RaghavanDonglu Zhang
Feb 7, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·C WeinzD Lang
Feb 7, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·D LangC Weinz
Feb 19, 2009·Journal of Thrombosis and Thrombolysis·Aneel A Ashrani, John A Heit
Aug 7, 2009·The New England Journal of Medicine·Michael Rud LassenRonald J Portman
Nov 27, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lifei WangScott J Grossman
May 4, 2010·Thrombosis Research·R J FriedmanUNKNOWN RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees
Dec 24, 2010·The New England Journal of Medicine·Michael Rud LassenUNKNOWN ADVANCE-3 Investigators
Dec 3, 2011·The Journal of the American Academy of Orthopaedic Surgeons·Michael A Mont, Joshua J Jacobs
Apr 5, 2012·American Journal of Hematology·Scott KaatzJack Ansell

❮ Previous
Next ❯

Citations

Mar 19, 2016·Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA·James D F CalderPaul W Ackermann
Mar 21, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Calvin H YehJeffrey I Weitz
Sep 18, 2018·European Journal of Orthopaedic Surgery & Traumatology : Orthopédie Traumatologie·Panayiotis K KarampinasSpyros G Pneumaticos
Aug 11, 2015·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Ranjan PathakAnthony A Donato
Apr 26, 2017·Archives of Orthopaedic and Trauma Surgery·Adriane MayerBernd Fink
Jan 2, 2021·Scientific Reports·Karsten KellerPhilipp Drees

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.